Pre-surgery neratinib plus hormone therapy with trastuzumab
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older, and postmenopausal
- Your breast cancer is invasive, stage I–III, and needs pre-surgery treatment (tumor larger than 10 mm and/or lymph node positive)
- Your tumor tests positive for HER2 and ER (ER is at least 10%)
- You must be able to get heart checks showing good pumping (LVEF at least 50%) and have acceptable blood test results
- You must have biopsy tissue saved from before treatment, and you can repeat a breast biopsy about 3 weeks after starting
- You should be taking letrozole or anastrozole (your clinician chooses)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests whether taking neratinib after completing a year of standard treatment can help prevent breast cancer from coming back in women who had a complete response to initial therapy but still have high-risk features.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.